Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mosaic Immunoengineering Inc (OP: CPMV )

0.3900 UNCHANGED
Streaming Delayed Price Updated: 9:40 AM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 75
Open 0.3900
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.3900
Today's Range 0.3900 - 0.3900
52wk Range 0.1020 - 1.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.
Via ACCESSWIRE
Mosaic ImmunoEngineering Announces Issuance of U.S. Patent Covering Cancer Treatment with Its Lead Immuno-Oncology Candidate MIE-101
Via ACCESSWIRE

Performance

YTD
-35.00%
-35.00%
1 Month
+24.60%
+24.60%
3 Month
-33.90%
-33.90%
6 Month
-22.16%
-22.16%
1 Year
-51.31%
-51.31%

More News

Read More
UPDATE: Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Platform
Via ACCESSWIRE
Mosaic ImmunoEngineering’s Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company’s Novel Immuno-Oncology Plat-form
Via ACCESSWIRE
Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Newly Published Data Further Support Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Exposures COVID-19
Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Exposures COVID-19
Spotlight Presentation at the World Molecular Imaging Congress Highlights Mosaic ImmunoEngineering's Immuno-Oncology and Modular Vaccine Platform Candidates
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Exposures COVID-19
Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Exposures COVID-19
Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering’s Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Exposures COVID-19
Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Exposures COVID-19
Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of Its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Exposures COVID-19
Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Exposures COVID-19
Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering’s Lead Intratumoral Immunotherapy Candidate, MIE-101
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Exposures COVID-19
Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Exposures COVID-19
Mosaic ImmunoEngineering Inc. Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.